Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
888
datasets available to search
ShareScore release 0.9.0
Dataset results
888 results for “insulin resistance”
Yogurt supplementation attenuates insulin resistance in obese mice by reducing metabolic endotoxemia and inflammation
Open the record for dataset details and reuse information.
Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver
Open the record for dataset details and reuse information.
Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial
<p>STUDY QUESTION</p> <p>Does acupuncture improve insulin sensitivity more effectively than metformin or sham acupuncture in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR)?</p> <p>SUMMARY ANSWER</p> <p>Among women with PCOS and IR, acupuncture was not more effective than metformin or sham acupuncture in improving insulin sensitivity.</p> <p>WHAT IS KNOWN ALREADY</p> <p>Uncontrolled trials have shown that acupuncture improved insulin sensitivity with fewer side effects compared with metformin in women with PCOS and IR. However, data from randomized trials between acupuncture and metformin or sham acupuncture are lacking.</p> <p>STUDY DESIGN, SIZE, DURATION</p> <p>This was a three-armed randomized controlled trial enrolling a total of 342 women with PCOS and IR from three hospitals between November 2015 and February 2018, with a 3-month follow-up until October 2018.</p> <p>PARTICIPANTS/MATERIALS, SETTING, METHODS</p> <p>Women aged from 18 to 40 years with PCOS and homeostasis model assessment of insulin resistance (HOMA-IR) ≥2.14 were randomly assigned (n = 114 per group) to receive true acupuncture plus placebo (true acupuncture), metformin plus sham acupuncture (metformin, 0.5 g three times daily) or sham acupuncture plus placebo (sham acupuncture) for 4 months, with an additional 3-month follow-up. True or sham acupuncture was given three times per week, and 0.5 g metformin or placebo was given three times daily. The primary outcome was change in HOMA-IR from baseline to 4 months after baseline visit. Secondary outcomes included changes in the glucose AUC during an oral glucose tolerance test, BMI and side effects at 4 months after baseline visit.</p> <p>MAIN RESULTS AND THE ROLE OF CHANCE</p> <p>After 4 months of treatment, the changes of HOMA-IR were –0.5 (decreased 14.7%) in the true acupuncture group, –1.0 (decreased 25.0%) in the metformin group and –0.3 (decreased 8.6%) in the sham acupuncture group, when compared with baseline. True acupuncture is not as effective as metformin in improving HOMA-IR at 4 months after baseline visit (difference, 0.6; 95% CI, 0.1–1.1). No significant difference was found in change in HOMA-IR between true and sham acupuncture groups at 4 months after baseline visit (difference, –0.2; 95% CI, –0.7 to 0.3). During the 4 months of treatment, gastrointestinal side effects were more frequent in the metformin group, including diarrhea, nausea, loss of appetite, fatigue, vomiting and stomach discomfort (31.6%, 13.2%, 11.4%, 8.8%, 14.0% and 8.8%, respectively). Bruising was more common in the true acupuncture group (14.9%).</p> <p>LIMITATIONS, REASONS FOR CAUTION</p> <p>This study might have underestimated the sample size in the true acupuncture group with 4 months of treatment to enable detection of statistically significant changes in HOMA-IR with fixed acupuncture (i.e. a non-personalized protocol). Participants who withdrew because of pregnancy did not have further blood tests and this can introduce bias.</p> <p>WIDER IMPLICATIONS OF THE FINDINGS</p> <p>True acupuncture did not improve insulin sensitivity as effectively as metformin in women with PCOS and IR, but it is better than metformin in improving glucose metabolism (which might reduce the risk of type 2 diabetes) and has less side effects. Metformin had a higher incidence of gastrointestinal adverse effects than acupuncture groups, and thus acupuncture might be a non-pharmacological treatment with low risk for women with PCOS. Further studies are needed to evaluate the effect of acupuncture combined with metformin on insulin sensitivity in these women.</p> <p>STUDY FUNDING/COMPETING INTEREST(S)</p> <p>This work was supported by grants 2017A020213004 and 2014A020221060 from the Science and Technology Planning Project of Guangdong Province. The authors have no conflicts of interest.</p> <p>TRIAL REGISTRATION NUMBER</p> <p>Clinicaltrials.gov number: NCT02491333.</p> <p>TRIAL REGISTRATION DATE</p> <p>8 July 2015.</p> <p>DATE OF FIRST PATIENT'S ENROLLMENT</p> <p>11 November 2015.</p>
Fig. 6 in Germacranolide- and guaianolide-type sesquiterpenoids from Achillea alpina L. reduce insulin resistance in palmitic acid-treated HepG2 cells via inhibition of the NLRP3 inflammasome pathway
Fig. 6. The inhibitory effects of 4 on the production of IL-1β and ROS in HepG2-IR cells. The expression levels of IL-1β were measured by ELISA analysis (A), Fluorescence intensity of ROS was recorded by a multimode microplate reader (B). ##P <0.01 vs CON group, *P <0.05, **P <0.01 vs PA treatment group.
Fig. 5 in Germacranolide- and guaianolide-type sesquiterpenoids from Achillea alpina L. reduce insulin resistance in palmitic acid-treated HepG2 cells via inhibition of the NLRP3 inflammasome pathway
Fig. 5. The glucose consumption assay of compounds 4–6, 10 and 11 in different concentrations. The concentrations of these compounds were from 1.56 to 50 μM, ROSI was the positive control. *p <0.05, **p <0.01, compared to the PA treatment group. ##p <0.01, compared to the control (CON) group.
Fig. 7 in Germacranolide- and guaianolide-type sesquiterpenoids from Achillea alpina L. reduce insulin resistance in palmitic acid-treated HepG2 cells via inhibition of the NLRP3 inflammasome pathway
Fig. 7. Inhibitory effects of 4 on the expression of proteins related to NLRP3 inflammasome in PA-induced HepG2-IR cells. Representative protein bands of Western blot (A and B). Densitometric analysis of the Western blot analysis results (C). Glibenclamide (1 μM, Gliben) was a positive control. ##P <0.01 vs CON group, *P <0.05, **P <0.01 vs PA treatment group.
Fig. 6 in Spiroganodermaines A G from Ganoderma species and their activities against insulin resistance and renal fibrosis
Fig. 6. Compounds inhibit renal fibrosis in vitro. (A) NRK-52E cells were treated with 20 μM for 48 h, and cell viability was determined by using the CCK-8 assay. (B, E and F) Compounds at 20 μM affect renal fibrosis-related protein expression. GW788388 was used as a positive control. (C) NRK-52E cells were treated with 5, 10 and 20 μM of ()-7 for 48 h, and cell viability was determined by using the CCK-8 assay. (D, G and H) Compound ()-7 dose-dependently inhibits fibronectin and α-SMA expression. GW788388 was used as a positive control. The results were represented Mean ± SEM. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001 compared with TGF-β1 alone. #P <0.05 ##P <0.01, ###P <0.001, and ####P <0.0001 compared with DMSO alone.
Fig. 5 in Spiroganodermaines A G from Ganoderma species and their activities against insulin resistance and renal fibrosis
Fig. 5. Attenuation of insulin-induced IR in myotubes. (A) C2C12 cell proliferation in response to compounds at 40 μM by CCK-8 assay. (B) C2C12 were treated with 40 μM for 24 h, and glucose uptake was determined. Metformin (Met) was used as a positive control. (C) Compound (+)-7 improves insulin-stimulated glucose uptake in IR model. (D–F) Expression of p-AKT and p-IRS1 were determined by Western blot. Compound (+)-7 improves attenuated insulin signal pathway disruption in dose-dependent manner. #P <0.05 and ###P <0.001 compared with no-insulin treatment control; *P <0.05 and **P <0.01 compared with insulin treatment alone; $$$P <0.001 and $$$$P <0.0001 compared with insulin treatment control.
Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery
ClinicalTrials.gov study NCT01930318. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss
ClinicalTrials.gov study NCT00766298. IPD Sharing: NO. Countries: 1. Publications: 6.
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
ClinicalTrials.gov study NCT01271777. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Effect of Insulin Resistance on Branched Chain Amino Acid Metabolism.
ClinicalTrials.gov study NCT04886973. IPD Sharing: NO. Countries: 1. Publications: 10.
Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients
ClinicalTrials.gov study NCT00384384. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Impact of Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
ClinicalTrials.gov study NCT04651842. IPD Sharing: Not stated. Countries: 1. Publications: 28.
Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
ClinicalTrials.gov study NCT02457286. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes Diet Treated
ClinicalTrials.gov study NCT03763669. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes
ClinicalTrials.gov study NCT04791371. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Microvascular Dysfunction and the Development of Whole-body Insulin Resistance
ClinicalTrials.gov study NCT02628301. IPD Sharing: UNDECIDED. Countries: 1. Publications: 9.
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
ClinicalTrials.gov study NCT00637520. IPD Sharing: Not stated. Countries: 1. Publications: 18.
Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity
ClinicalTrials.gov study NCT00636142. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.